This study was designed to study the therapeutic effects of Deanxit in treating functional dyspepsia. Methods: 168 functional dyspepsia patients were collected. According to the Roma III standard, symptoms include early satiety, epigastric distention, epigastric pain, etal. All patients were randomly assigned to the Deanxit group and the control group. The former had 78 patients and took Mosapride 15 mg daily and Deanxit 10.5 mg daily, while the latter had 90 patients and took Mosapride 15 mg daily and Vitamin B6 10 mg daily. Both groups took medicine for 4 weeks. The scoring for the digestive tract symptoms, HAMA score, and HAMD score were evaluated before

and after treatment. Results: The total effect rate was 88.2% in the Deanxit Group and 78.3% in the control Group. There was statistical difference between the two groups (P < 0.05). There was statistical difference in the scoring for the digestive tract symptoms, HAMA score, and HAMD score (P < 0.05, PLX-4720 P < 0.01). There was no statistical difference in the improvement of defecation frequency score between the two groups after treatment (P > 0.05). There was no statistical difference in the side effects between the two groups. Conclusion: Deanxit could effectively treat dyspepsia selleck accompanied with anxiety and/or depression. It had superiorities in improving symptoms. Key Word(s): 1. Deanxit; 2. dyspepsia; 3. effect Presenting Author:

MASATOSHI MABUCHI Additional Authors: ICHIRO YASUDA, SHINPEI DOI, NORITAKA OZAWA,

TAKUJI IWASHITA Corresponding Author: MASATOSHI MABUCHI Affiliations: Teikyo University Mizonokuchi Hospital, Teikyo University Mizonokuchi Hospital, Teikyo University Mizonokuchi Hospital, Gifu University Hospital Objective: Gastrointestinal Tenofovir order submucosal tumors (SMT) include various diseases from benign to malignant. EUS-FNA is a safe and reliable technique to obtain pathological sample from SMT. However, it is still unclear whether such FNA specimen has sufficient amount and quality for detailed assessment including immunohistological staining, which is mandatory to make a diagnosis of gastrointestinal stromal tumor (GIST). We evaluated the accuracy of diagnosis of gastrointestinal SMT by EUS-FNA using a 19-gauge needle. Especially in the diagnosis of GIST, the correlation with risk classification between FNA and surgical specimens was also examined. Methods: Our EUS database between July 2004 and March 2014 was reviewed to identify the patients who had been attempted EUS-FNA using a 19-gauge needle for SMT. In the patients who underwent surgery for GIST, MIB-1 index and Fletcher risk classification were compared between the FNA and surgical specimens and the correlations was assessed by weighted kappa coefficient. Results: A total of 93 patients (52 female; median age 66 [range, 24–86]) were identified. SMT was located at stomach in 76, esophagus in 11, duodenum in 3, and rectum in 3. The median size was 28 mm (range, 11–135 mm).